Literature DB >> 29908220

An Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System for Defining External Beam Radiation Therapy Boost Volumes.

Radka Stoyanova1, Felix Chinea1, Deukwoo Kwon2, Isildinha M Reis2, Yohann Tschudi1, Nestor A Parra1, Adrian L Breto1, Kyle R Padgett1, Alan Dal Pra1, Matthew C Abramowitz1, Oleksandr N Kryvenko3, Sanoj Punnen4, Alan Pollack5.   

Abstract

PURPOSE: To develop a prostate tumor habitat risk scoring (HRS) system based on multiparametric magnetic resonance imaging (mpMRI) referenced to prostatectomy Gleason score (GS) for automatic delineation of gross tumor volumes. A workflow for integration of HRS into radiation therapy boost volume dose escalation was developed in the framework of a phase 2 randomized clinical trial (BLaStM). METHODS AND MATERIALS: An automated quantitative mpMRI-based 10-point pixel-by-pixel method was optimized to prostatectomy GSs and volumes using referenced dynamic contrast-enhanced and apparent diffusion coefficient sequences. The HRS contours were migrated to the planning computed tomography scan for boost volume generation.
RESULTS: There were 51 regions of interest in 12 patients who underwent radical prostatectomy (26 with GS ≥7 and 25 with GS 6). The resultant heat maps showed inter- and intratumoral heterogeneity. The HRS6 level was significantly associated with radical prostatectomy regions of interest (slope 1.09, r = 0.767; P < .0001). For predicting the likelihood of cancer, GS ≥7 and GS ≥8 HRS6 area under the curve was 0.718, 0.802, and 0.897, respectively. HRS was superior to the Prostate Imaging, Reporting and Diagnosis System 4/5 classification, wherein the area under the curve was 0.62, 0.64, and 0.617, respectively (difference with HR6, P < .0001). HRS maps were created for the first 37 assessable patients on the BLaStM trial. There were an average of 1.38 habitat boost volumes per patient at a total boost volume average of 3.6 cm3.
CONCLUSIONS: An automated quantitative mpMRI-based method was developed to objectively guide dose escalation to high-risk habitat volumes based on prostatectomy GS.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29908220      PMCID: PMC6245650          DOI: 10.1016/j.ijrobp.2018.06.003

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  21 in total

1.  Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.

Authors:  W James Morris; Scott Tyldesley; Sree Rodda; Ross Halperin; Howard Pai; Michael McKenzie; Graeme Duncan; Gerard Morton; Jeremy Hamm; Nevin Murray
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-11-24       Impact factor: 7.038

2.  Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores.

Authors:  Andreas Wibmer; Hedvig Hricak; Tatsuo Gondo; Kazuhiro Matsumoto; Harini Veeraraghavan; Duc Fehr; Junting Zheng; Debra Goldman; Chaya Moskowitz; Samson W Fine; Victor E Reuter; James Eastham; Evis Sala; Hebert Alberto Vargas
Journal:  Eur Radiol       Date:  2015-05-21       Impact factor: 5.315

Review 3.  Boosting imaging defined dominant prostatic tumors: a systematic review.

Authors:  Glenn Bauman; Masoom Haider; Uulke A Van der Heide; Cynthia Ménard
Journal:  Radiother Oncol       Date:  2013-06-20       Impact factor: 6.280

4.  Mapping Tumor Hypoxia In Vivo Using Pattern Recognition of Dynamic Contrast-enhanced MRI Data.

Authors:  Radka Stoyanova; Kris Huang; Kiri Sandler; Hyungjoon Cho; Sean Carlin; Pat B Zanzonico; Jason A Koutcher; Ellen Ackerstaff
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

5.  Average Weight of Seminal Vesicles: An Adjustment Factor for Radical Prostatectomy Specimens Weighed With Seminal Vesicles.

Authors:  George A Tjionas; Jonathan I Epstein; Sean R Williamson; Mireya Diaz; Mani Menon; James O Peabody; Nilesh S Gupta; Dipen J Parekh; Richard J Cote; Merce Jorda; Oleksandr N Kryvenko
Journal:  Int J Surg Pathol       Date:  2015-08-25       Impact factor: 1.271

Review 6.  Quantitative imaging in cancer evolution and ecology.

Authors:  Robert A Gatenby; Olya Grove; Robert J Gillies
Journal:  Radiology       Date:  2013-10       Impact factor: 11.105

Review 7.  Changes in prostate cancer grading: Including a new patient-centric grading system.

Authors:  Oleksandr N Kryvenko; Jonathan I Epstein
Journal:  Prostate       Date:  2015-12-28       Impact factor: 4.104

8.  Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology.

Authors:  Sofie Isebaert; Laura Van den Bergh; Karin Haustermans; Steven Joniau; Evelyne Lerut; Liesbeth De Wever; Frederik De Keyzer; Tom Budiharto; Pieter Slagmolen; Hendrik Van Poppel; Raymond Oyen
Journal:  J Magn Reson Imaging       Date:  2012-11-21       Impact factor: 4.813

Review 9.  Radiotherapy Boost for the Dominant Intraprostatic Cancer Lesion-A Systematic Review and Meta-Analysis.

Authors:  Finn Edler von Eyben; Timo Kiljunen; Aki Kangasmaki; Kalevi Kairemo; Rie von Eyben; Timo Joensuu
Journal:  Clin Genitourin Cancer       Date:  2015-12-17       Impact factor: 2.872

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more
  7 in total

Review 1.  The role of radiomics in prostate cancer radiotherapy.

Authors:  Rodrigo Delgadillo; John C Ford; Matthew C Abramowitz; Alan Dal Pra; Alan Pollack; Radka Stoyanova
Journal:  Strahlenther Onkol       Date:  2020-08-21       Impact factor: 3.621

2.  Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Radiation Therapy.

Authors:  Alan Pollack; Felix M Chinea; Elizabeth Bossart; Deukwoo Kwon; Matthew C Abramowitz; Charles Lynne; Merce Jorda; Brian Marples; Vivek N Patel; Xiaodong Wu; Isildinha Reis; Matthew T Studenski; Javier Casillas; Radka Stoyanova
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-02-19       Impact factor: 7.038

3.  Prostate cancer GTV delineation with biparametric MRI and 68Ga-PSMA-PET: comparison of expert contours and semi-automated methods.

Authors:  Nathan Hearn; John Blazak; Philip Vivian; Dinesh Vignarajah; Katelyn Cahill; Daisy Atwell; Jim Lagopoulos; Myo Min
Journal:  Br J Radiol       Date:  2021-01-28       Impact factor: 3.039

Review 4.  Magnetic resonance imaging (MRI)-based radiomics for prostate cancer radiotherapy.

Authors:  Fei Yang; John C Ford; Nesrin Dogan; Kyle R Padgett; Adrian L Breto; Matthew C Abramowitz; Alan Dal Pra; Alan Pollack; Radka Stoyanova
Journal:  Transl Androl Urol       Date:  2018-06

5.  Habitats in DCE-MRI to Predict Clinically Significant Prostate Cancers.

Authors:  Nestor Andres Parra; Hong Lu; Jung Choi; Kenneth Gage; Julio Pow-Sang; Robert J Gillies; Yoganand Balagurunathan
Journal:  Tomography       Date:  2019-03

6.  Automatic Detection of Prostate Tumor Habitats using Diffusion MRI.

Authors:  Yohann Tschudi; Alan Pollack; Sanoj Punnen; John C Ford; Yu-Cherng Chang; Nachiketh Soodana-Prakash; Adrian L Breto; Deukwoo Kwon; Felipe Munera; Matthew C Abramowitz; Oleksandr N Kryvenko; Radka Stoyanova
Journal:  Sci Rep       Date:  2018-11-14       Impact factor: 4.379

7.  The Role of Multiparametric Magnetic Resonance in Volumetric Modulated Arc Radiation Therapy Planning for Prostate Cancer Recurrence After Radical Prostatectomy: A Pilot Study.

Authors:  Angela Sardaro; Barbara Turi; Lilia Bardoscia; Cristina Ferrari; Giuseppe Rubini; Angela Calabrese; Federica Ammirati; Antonietta Grillo; Annamaria Leo; Filomenamila Lorusso; Antonio Santorsola; Antonio Amato Stabile Ianora; Arnaldo Scardapane
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.